World Bronchiectasis Conference recordings- topics and times
It’s difficult to view the recordings without any indication of when talks begin on the 10 hour recordings. I marked the name of the talk and the time it begins on the recording to help us. It is best to view the recordings on a computer as it is easier to move the slide.
Enjoy,
Linda Esposito
Wednesday July 19th
Etiologies & Diagnostic Evaluation of Bronchiectasis–40 mins
Anne O’Donnell
Genetics—57 mins
Kenneth Oliver
Pathophysiology & Protracted Bacterial Bronchitis–1:17
Pamela McShane
Inflammation–1:36
James Chalmers
Microbiome–3:15
Sanjay Chotirmall
Immunodeficiencies–3:30
Michal Shteinberg
Alpha 1 Antitrypsin as potential therapy for BE–4:07
Paul King
Prevalence & Factors Asscoicated w fungi in the Sputum & BE–4:28
Pamela McShane
COPD/BE overlap–6:11
Mark Metersky
Asthma & Biologic Therapy in BE–6:25
Stefano Aliberti
COVID-19 & other viruses in BE–6:39
Lucy Morgan
ABPA, Fungal Infections and BE–7:00
Caroline Baxter
Management of Exacerbations–9:33
Adam Hill
Inhaled Antibiotics–9:48
Charles Haworth
Transplant in BE & NTM–10:08
Jake Natalini
Thursday, July 20
Environment–42 mins
Rachel Thomson
Biofilm–58
Theodore Marras
Microbiome & NTM–1:15
Leopoldo Segal
Reflux, Aspiration & Swallow–1:36
Paul Kwak
Clinical Application of the Microbiome–3:11
Imran Sulaiman
Distinct Features of the Lower Airway Microbiome NTM/BE–4:21
Shivani Singh
Recurrence, Reinfection & Drug Levels–5:50
Jakko van Ingen
2v3 Antibiotics for MAC–6:06
Kevin Winthrop and David Griffith
Management of Refractory MAC–6:35
Doreen Addrizzo-Harris
Management of M. Abscessus–6:56
Shannon Kasperbauer
Surgical Management of Reflux–7:47
Tanuja Damani
Bacteriophage–8:11
Jerry Nick
Inhaled NO–8:27
Patrick Flume
Other Emerging Therapies–8:43
Charles Daley
Interested in more discussions like this? Go to the MAC & Bronchiectasis Support Group.
Brensocatib was discussed. It has 1700 participants and is no longer recruiting. Because it’s a 52 week study there will be at least another 10 months of accumulating data. And then everything needs to be analyzed. There’s a possibility of it coming to market in 2025.
Linda, the great news of possible new treatment’s & therapies is great news. I have Traction Bronchiectasis & Fibrosis caused by NSIP. I purchased a Ombra nebulizer, as I liked the idea of breath activation. But it takes me 30-35 mins to nebulize albuterol & an additional 30-45 mins for 7% saline. Am I doing something wrong?
One reason could be some people are unable to take deep inhalations and easily activate the BAN feature of the cup. One way to help yourself is to push down on the green button. Or it might be better to use continuous mode. But I also agree that putting less medication into our home air is always best.
Do you know for sure that you need the albuterol? Were you tested during your PFTs? If you don’t need it, if it doesn’t make a difference, if you don’t have bronchospasm, you might be able to eliminate it.
Another option might be using a puffer, an inhaler, instead of nebulizing. That also would cut out time from your airway clearance routine.
These are issues for you to discuss with your medical team. Do not make any changes on your own.
Linda
Some of the speakers from World Bronchiectasis Conference, referenced above, also spoke at the freely available Bronchiectasis Patient Conference 2023. Subtitling and speed options makes it efficient to view.
https://europeanlung.org/en/get-involved/events/bronchiectasis-patient-conference-2023/
Thank you so much 'beclear' for listing the times for our ease!
Very kind.
This will be my weekend activity!
Enjoy!
Thank you so much to the link to this conference! I have found the speakers to be both helpful and encouraging. I’m particularly excited about the prospects of new drugs and treatments that were discussed in session 3.
My pleasure! This coming week I’m going to share information about a very exciting study that’s still recruiting.
Hi everyone,
Don’t forget this is the last week to listen to the World Bronchiectasis Conference recordings!
I’ve been reviewing those I find most interesting, including the keynote addresses. Dr. James Chalmers in his keynote said that with access to large database registries, “I am excited about where we are in bronchiectasis. I think we’ve gone from a thousand unanswered questions to having huge cohorts and the ability to do research at scale.”
It was reassuring to hear Dr Chalmers, a top researcher and clinician, make this announcement the day of the conference. I also felt proud to be participating in the US Bronchiectasis Research Registry. I was first enrolled in the registry four years ago as a new patient at NYU Langone and now, every year, we update my information.
This is the link to learn more about the US registry and which centers participate (Mayo participates!):
https://www.bronchiectasisandntminitiative.org/Research/Registry/Bronchiectasis-and-NTM-Research-Registry
There are registries throughout the world and if you have the opportunity to join one, I hope you will seriously consider it.
These registries enable scientists to do research on potential new therapies and hopefully, in time, find a cure.
Best,
Linda Esposito
May I know the link to listen.